Moreover, these compounds were only weakly active in the stimulation of amylase release from guinea pig pancreatic acini (EC50 > 10,000 nM) and were unable to induce contractions in the guinea pig ileum (to 10-6 M). The two cyclic CCK analogues, therefore, appear to be synthetic ligands exhibiting both high affinity and high selectivity for central CCK binding sites. These compounds could help clarify the respective role of central and peripheral receptors for various CCK-8-induced pharmacological effects.
The C-terminal octapeptide of cholecystokinin, CCK-8 [Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2], is a hormonal regulator of pancreatic secretion (1-3) that also can induce gallbladder contraction (1, 4, 5) and increase gut motility (4) . Moreover, CCK-8 is present in high concentrations in the mammalian brain (6) (7) (8) (9) , where it could be a neurotransmitter or neuromodulator, as suggested from various biochemical and pharmacological studies (10) (11) (12) (13) (14) (15) (16) . Extensive binding studies have clearly shown that the ligand specificities differ greatly for central and peripheral receptors (17) (18) (19) (20) , and irreversible labeling experiments have revealed entities with different molecular weights for pancreas and brain binding sites (21) . Nevertheless, the respective roles of both types of receptors in many CCK-8-induced pharmacological responses are still controversial, especially when peripheral or even intracerebroventricular routes of administration have been used (22, 23) . Potent ligands, highly specific for either class of receptors, are therefore essential for understanding the physiological role of CCK. Moreover, CCK is colocalized with dopamine in the mesolimbic pathway (24) and could modulate dopaminergic transmission (11, 25) . Consequently, in preliminary studies CCK-8 was suggested to exhibit neuroleptic properties in the human and thus was proposed as a relevant compound for the treatment of various psychiatric disorders (26, 27) . However, in more extensive clinical studies, no significant antipsychotic effect was demonstrated (28) (29) (30) (31) (32) . Clearly centrally selective, long-acting CCK agonists and antagonists that cross the blood-brain barrier would have application for more rigorous conclusive clinical trials.
The existence of several types of CCK receptors implies different biologically active conformations for the native peptide. Thus, constrained structures could be designed to favor recognition of one particular receptor. This approach has been successfully undertaken recently, leading to nonpeptidic antagonists that are highly specific for peripheral CCK receptors (33, 34) . For enkephalins (35, 36) , probes specific to the several opioid receptors were obtained by cyclizing the peptide to mimic the favorable conformation of native peptide (37, 38 tTo whom reprint requests should be addressed.
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MATERIALS AND METHODS
In the brain, compounds I and II inhibited, with a high affinity, the specific binding of [3H]Boc[Ahx28 "]CCK- (27) (28) (29) (30) (31) (32) (33) in a concentration-dependent manner (Fig. 3) . Compound II (Ki, 0.49 nM) was found to be more potent than compound I (Ki, 5.1 nM) and almost equipotent to CCK-8 (Ki, 0.30 nM). The same order of affinities was found when 125I-BHCCK-8 was used (CCK-8: IC50, 0.42 nM; compound I: IC50, 10.2; compound II: IC50, 0.92) ( Table 1) .
In contrast to their strong interaction with central CCK binding sites, compounds I and II were poor ligands for pancreatic receptors (Fig. 3, Table 1 ), as shown by displacement of both the tritiated (CCK-8: K,, 0.9 nM; compound I: Ki, 910 nM; compound II: K,, 970 nm) and the iodinated Scatchard (54) in the presence of these compounds. The weak interaction of the two cyclic analogues with the peripheral CCK receptors was further examined by assessing their potency in two in vitro peripheral bioassays-i.e., stimulation of amylase release from pancreatic acini and induction of contractions in the guinea pig ileum.
In agreement with their low affinity for pancreatic CCK receptors, compounds I and II were only weakly active in stimulating amylase release from pancreatic acini (Fig. 5) (CCK-8: EC50, 0.13 nM; compound I: EC50 > 10,000 nM; compound II: EC50 > 10,000 nM). Similarly, these compounds were unable to induce the contractions of guinea pig ileum when used at concentrations up to 10-6 M (EC50 of CCK-8 in this assay was 0.68 nM). Note that in the amylase release test, compound I was slightly more potent than compound II, despite the similar affinities displayed by these two peptides for pancreatic receptors. Nevertheless, the weak peripheral activity of compound II was clearly lower by at least a factor of 100,000 than that of CCK-8. In addition, no antagonistic activity was detected until a concentration of 10-6 M The cyclization of the N-terminal part of CCK therefore opens the possibility of selectively modulating the interactions with central CCK receptors by small changes directed towards the cyclic portion of the molecule. Structure-activity studies on such cyclic compounds, combined with conformational investigations, could better define the prerequisite structure for selective interaction with central CCK receptors.
Cyclic peptide compounds I and II are extremely selective synthetic ligands for brain CCK receptors of guinea pig and, accordingly, could be valuable for investigating CCK function in the central nervous system. 
